CHICAGO – The validity of pathological complete response – hailed as a surrogate marker that could dramatically speed drug development – came under attack in a high-profile plenary session and a press briefing at the American Society of Clinical Oncology meeting on June 1 with news that the ALTTO adjuvant breast cancer study failed.
At a June 1 press briefing, outgoing ASCO president Clifford Hudis said that the ALTTO results have “profound long-term implications”...